As it is known that approximately 80% of breast cancer cases are estrogen receptor positive (ER+); an estrogen derivative, 17α-ethynylestradiol (EE2) was chosen as a targeting ligand thanks to its high specificity toward ER+. This evidence concerns the gene ESR1 and breast carcinoma.